Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPL | P40238 | 2/20 | 0.47 |
| ▸ | MYC | P01106 | 9/20 | 0.43 |
| ▸ | WDR5 | P61964 | 9/20 | 0.43 |
| ▸ | KDM1A | O60341 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | CDC7 | O00311 | 1/20 | 0.35 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31311375 | 1.00 | MPL (0.47) | MPLMYCWDR5KDM1AKDM4E | |
| SCHEMBL31311334 | 0.87 | MPL (0.47) | MPLMYCWDR5KDM1AKDM4E | |
| SCHEMBL1852196 | 0.83 | MYC (0.61) | MYCWDR5KDM4EALDH1A1MAPT | |
| SCHEMBL21283241 | 0.82 | KDM1A (0.38) | MPLKDM1ACYP11B1CYP11B2CDC7 | |
| SCHEMBL21283199 | 0.82 | KDM1A (0.43) | KDM1AKDM4ECYP11B1CYP11B2CDC7 | |
| SCHEMBL1848775 | 0.81 | ADORA1 (0.55) | MYCWDR5KDM4EMAPTCDC7 | |
| SCHEMBL30309309 | 0.81 | ADORA1 (0.55) | MYCWDR5KDM4EMAPTCDC7 | |
| SCHEMBL28724215 | 0.80 | MYC (0.61) | MYCWDR5KDM4EALDH1A1MAPT | |
| SCHEMBL1849138 | 0.80 | MYC (0.43) | MPLMYCWDR5KDM4EALDH1A1 | |
| SCHEMBL25247416 | 0.79 | MPL (0.69) | MPLMYCWDR5KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731206-A2 | COMPOSITIONS AND METHODS OF USE TO TREAT 12-LIPOXYGENASE (12-LOX) MEDIATED DISEASES | Veralox Therapeutics Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| WO-2024264032-A2 | COMPOSITIONS AND METHODS OF USE TO TREAT 12-LIPOXYGENASE (12-LOX) MEDIATED DISEASES | VERALOX THERAPEUTICS INC. (US) | 2024-12-26 | — | — | WO | disclosed |
| US-11591342-B2 | Heterocyclic compound, application thereof and pharmaceutical composition comprising same | Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) | 2023-02-28 | — | — | US | disclosed |
| CN-111620865-B | Heterocyclic compound, application thereof and pharmaceutical composition containing same | 苏州信诺维医药科技股份有限公司 | 2021-06-11 | — | — | CN | disclosed |
| EP-3753943-A1 | HETEROCYCLIC COMPOUND, APPLICATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) | 2020-12-23 | — | — | EP | disclosed |
| EP-3753943-A1 | HETEROCYCLIC COMPOUND, APPLICATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) | 2020-12-23 | — | — | EP | disclosed |
| US-20200369676-A1 | HETEROCYCLIC COMPOUND, APPLICATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) | 2020-11-26 | — | — | US | disclosed |
| US-20200369676-A1 | HETEROCYCLIC COMPOUND, APPLICATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) | 2020-11-26 | — | — | US | disclosed |
| CN-111620864-A | Heterocyclic compound, application thereof and pharmaceutical composition containing same | 苏州信诺维医药科技有限公司 | 2020-09-04 | — | — | CN | disclosed |
| CN-111620865-A | Heterocyclic compound, application thereof and pharmaceutical composition containing same | 苏州信诺维医药科技有限公司 | 2020-09-04 | — | — | CN | disclosed |
| CN-110156772-B | Heterocyclic compound, application thereof and pharmaceutical composition containing same | 苏州信诺维医药科技有限公司 | 2020-08-07 | — | — | CN | disclosed |
| CN-110156772-A | Heterocyclic compound, application thereof and pharmaceutical composition containing same | 苏州信诺维医药科技有限公司 | 2019-08-23 | — | — | CN | disclosed |
| WO-2019158107-A1 | HETEROCYCLIC COMPOUND, APPLICATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 苏州信诺维医药科技有限公司 | 2019-08-22 | — | — | WO | disclosed |
| CN-101835766-B | As adenosine A1Receptor antagonist compounds | PALOBIOFARMA SL | 2013-09-25 | — | — | CN | disclosed |
| US-8410282-B2 | Compounds as adenosine A1 receptor antagonists | PALOBIOFARMA, S.L. (ES) | 2013-04-02 | — | — | US | disclosed |
| EP-2197860-B1 | NEW COMPOUNDS AS ADENOSINE A1 RECEPTOR ANTAGONISTS | PALOBIOFARMA SL (ES) | 2011-05-25 | — | — | EP | disclosed |
| US-20100311703-A1 | NEW COMPOUNDS AS ADENOSINE A1 RECEPTOR ANTAGONISTS | PALOBIOFARMA, S.L. (ES) | 2010-12-09 | — | — | US | disclosed |
| EP-2197860-A1 | NEW COMPOUNDS AS ADENOSINE A1 RECEPTOR ANTAGONISTS | Palobiofarma, S.L. (ES) | 2010-06-23 | — | — | EP | disclosed |
| WO-2009044250-A1 | NEW COMPOUNDS AS ADENOSINE A1 RECEPTOR ANTAGONISTS | PALOBIOFARMA, S.L. (ES) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11591342-B2 | Heterocyclic compound, application thereof and pharmaceutical composition comprising same | ENPP2, ATXN10, PCSK9 | MPL 1096/4885MYC 4129/4885WDR5 3667/4885 |
| US-20200369676-A1 | HETEROCYCLIC COMPOUND, APPLICATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | ENPP2, ATXN10, PCSK9 | MPL 1096/4885MYC 4129/4885WDR5 3667/4885 |
| US-20100311703-A1 | NEW COMPOUNDS AS ADENOSINE A1 RECEPTOR ANTAGONISTS | ADORA1, ADORA2A, ADORA3 | MPL 2140/4885MYC 3683/4885WDR5 4002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.